LYON, France, May well 31, 2022–(Small business WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical firm producing innovative remedies for persistent major disorders with metabolic pathophysiology, which include non-alcoholic steatohepatitis (NASH) and exceptional metabolic diseases, currently announces that the Poxel staff will take part in many forthcoming investor and scientific conferences in June 2022.
Jefferies 2022 World Health care Conference (in individual) – New York, New York, United states
Day: June 8-10, 2022
Thomas Kuhn, CEO and other customers of the Poxel administration crew will be available for a person-on-just one in-individual meetings on June 9-10, 2022. The Firm presentation is scheduled for June 10 at 11:00am ET.
JMP Securities 2022 Lifestyle Science Meeting (in person) – New York, New York, United states
Day: June 15-16, 2022
Thomas Kuhn, CEO and other customers of the Poxel management team will be obtainable for a person-on-one in-particular person conferences on June 16, 2022. The Company presentation is scheduled for June 16 at 12:30pm ET.
2022 United Leukodystrophy Foundation Scientific Symposium – Itasca, Illinois, Usa
Date: June 23-25, 2022
David Moller, Govt Vice President, Chief Scientific Officer of Poxel, will current on the Company’s adrenoleukodystrophy (ALD) scientific method on Friday, June 24. Poxel is a sponsor of this scientific symposium.
8th Congress of the European Academy of Neurology (in person) – Vienna, Austria
Date: June 25-28, 2022
Poxel will existing an e-poster on its drug prospect PXL770 entitled: “Likely Therapeutic Utility of Immediate AMP Kinase Activation for X-Connected Adrenoleukodystrophy (ALD)”. Also, Sophie Bozec, PhD, Senior Vice President, R&D Pharmacology and Scientific Interaction, will deliver a presentation: “Deuterium-Stabilized (R)-Pioglitazone, PXL065, for Procedure of X-Connected Adrenoleukodystrophy (ALD)”.
About Poxel SA
Poxel is a scientific phase biopharmaceutical organization creating modern solutions for continual critical conditions with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and uncommon problems. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting long-term and rare metabolic health conditions. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Section 2 demo (Future-1). PXL770, a 1st-in-class direct AMPK activator, has effectively finished a Section 2a evidence-of-idea trial for the treatment of NASH, which satisfied its objectives. For the uncommon inherited metabolic condition, adrenoleukodystrophy (ALD), the firm intends to initiate Phase 2a evidence of concept experiments with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s to start with-in-course guide item that targets mitochondrial dysfunction, has been approved and released for the cure of kind 2 diabetic issues in Japan. Poxel expects to receive royalties and revenue-dependent payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, South Korea, Taiwan and 9 other Southeast Asian nations. The Business intends to deliver more development as a result of strategic partnerships and pipeline advancement. Stated on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For extra facts, remember to go to: www.poxelpharma.com
Watch source variation on businesswire.com: https://www.businesswire.com/news/residence/20220531005858/en/
Contacts – Trader relations / Media
Investor Relations & Interaction Senior Director
+33 6 99 81 08 36
Senior Vice President, Trader Relations & Conversation
Emmanuel Huynh or Arthur Rouillé
+33 1 44 71 94 94